• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Capricor Therapeutics Inc.

    4/30/25 10:58:05 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CAPR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Capricor Therapeutics Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    14070B309

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    14070B309


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    49,251.00
    7Sole Dispositive Power

    2,171,616.00
    8Shared Dispositive Power

    92,375.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,263,991.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.95 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Capricor Therapeutics Inc
    (b)Address of issuer's principal executive offices:

    8840 Wilshire Blvd, 2nd Floor, Beverly Hills, CA, 90211
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    14070B309
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2263991
    (b)Percent of class:

    4.95  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    49251

     (iii) Sole power to dispose or to direct the disposition of:

    2171616

     (iv) Shared power to dispose or to direct the disposition of:

    92375

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:04/30/2025
    Get the next $CAPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CAPR

    DatePrice TargetRatingAnalyst
    10/21/2024$35.00Overweight
    Piper Sandler
    5/17/2024$14.00Outperform
    Oppenheimer
    1/5/2024$8.00Overweight
    Cantor Fitzgerald
    10/26/2022$15.00Buy
    Ladenburg Thalmann
    1/31/2022$14.00 → $18.00Buy
    HC Wainwright & Co.
    10/11/2021$9.00 → $14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CAPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Nippon Shinyaku Co Ltd bought $14,999,998 worth of shares (2,798,507 units at $5.36), increasing direct ownership by 65% to 7,090,351 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      9/24/24 4:01:08 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Musket David B bought $1,128 worth of shares (410 units at $2.75), increasing direct ownership by 1% to 31,536 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      10/13/23 1:59:57 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collier Earl M Jr bought $28,300 worth of shares (10,000 units at $2.83), increasing direct ownership by 59% to 26,856 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      10/12/23 9:15:07 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

      SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

      11/8/24 9:00:23 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

      SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

      9/24/24 4:03:22 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

      SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

      8/23/24 4:01:31 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Leadership Updates

    Live Leadership Updates

    See more
    • Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

      SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024. "We are thrilled to be joining the Russell 2000® Index, a testament to our Company's progress across our pipeline marked by significant advancements in our lead program for the treatment of Duchenne muscular dystrophy," said Linda Marbán, Ph.D., Capricor's chief executive officer. "This milestone reflects Ca

      7/1/24 9:00:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

      SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately. Mr. Kelliher, Group Vice President of M&A and Business Development at Horizon Therapeutics, brings to Capricor extensive expertise in business development, strategy, finance and operational leadership across the life sciences industry. "It is a pleasure to welcome Mike to our Board of Directors, who has an extraor

      9/6/23 9:00:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors

      SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced the appointment of Philip J. Gotwals, Ph.D., to its Board of Directors, effective immediately. Dr. Gotwals, most recently the Global Head, Vice President of Business Development and Licensing at Novartis Institutes for Biomedical Research, brings his strategic vision for research, innovation for drug development and valuable industry experience to the Company. "It is a pleasure to welcome Philip to our Board of Directo

      7/24/23 8:30:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Capricor Therapeutics with a new price target

      Piper Sandler initiated coverage of Capricor Therapeutics with a rating of Overweight and set a new price target of $35.00

      10/21/24 7:35:33 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Capricor Therapeutics with a new price target

      Oppenheimer initiated coverage of Capricor Therapeutics with a rating of Outperform and set a new price target of $14.00

      5/17/24 7:29:53 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Capricor Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Capricor Therapeutics with a rating of Overweight and set a new price target of $8.00

      1/5/24 7:28:46 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Marban Linda exercised 25,000 shares at a strike of $1.39 and disposed of 12,500 shares, increasing direct ownership by 6% to 211,104 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      3/5/25 5:00:13 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF FINANCIAL OFFICER Bergmann Anthony exercised 2,500 shares at a strike of $1.39, increasing direct ownership by 44% to 8,223 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      3/4/25 7:00:17 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Litvack Frank exercised 25,000 shares at a strike of $1.39 and covered exercise/tax liability with 2,543 shares, increasing direct ownership by 21% to 129,839 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      3/4/25 7:00:13 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

      SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13. Title:Capricor Therapeutics First Quarter 2025 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Tuesday, May 13, 2025Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 73741Participants can use g

      5/6/25 9:15:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

      -Company remains on track for PDUFA target action date of August 31, 2025- -Advisory committee meeting to be held in advance of target action date-   SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) --  Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy. During

      5/5/25 8:00:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OmniAb Announces Two New Appointments to its Board of Directors

      Philip Gotwals, Ph.D. and Steve Crouse bring strategic and operational experience in business development and global tools and technology OmniAb, Inc. (NASDAQ:OABI) today announced the appointments of Philip J. Gotwals, Ph.D., and Steve Crouse to its Board of Directors. OmniAb also announced the departure of Director Sarah Boyce, who is stepping down following nearly six years of service during a period of key strategic acquisitions and the significant expansion of the scope and size of OmniAb's partnership base. These Board changes are effective immediately and increase the number of Directors to seven. "We're delighted to welcome Phil and Steve to our Board of Directors. Their extensive

      4/21/25 8:00:00 AM ET
      $CAPR
      $OABI
      $TECH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Biological Products (No Diagnostic Substances)

    $CAPR
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Capricor Therapeutics Inc.

      SCHEDULE 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

      4/30/25 10:58:05 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Capricor Therapeutics Inc.

      DEF 14A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

      4/8/25 5:15:26 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics Inc. filed SEC Form 8-K: Leadership Update

      8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

      4/8/25 5:00:12 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Financials

    Live finance-specific insights

    See more
    • Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

      SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13. Title:Capricor Therapeutics First Quarter 2025 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Tuesday, May 13, 2025Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 73741Participants can use g

      5/6/25 9:15:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

      SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the fourth quarter and full year ended December 31, 2024, after the market close on Wednesday, March 19, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on March 19. Title:Capricor Therapeutics Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Wednesday, March 19, 2025Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-18

      3/11/25 9:00:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

      SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the third quarter ended September 30, 2024, after the market close on Wednesday, November 13, 2024. Management will then host a webcast and conference call at 4:30 p.m. ET on November 13. Title:Capricor Therapeutics Third Quarter 2024 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Wednesday, November 13, 2024Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 680

      11/5/24 9:00:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care